- Home
- CGEM
as 05-20-2024 12:33pm EST
Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 1.3B | IPO Year: | 2021 |
| Target Price: | $31.00 | AVG Volume (30 days): | 745.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.13 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.64 - $30.19 | Next Earning Date: | 05-15-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 864.72% |
Share on Social Networks:
Stock Insider Trading Activity of Cullinan Oncology Inc. (CGEM)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Michaelson Jennifer | CGEM | Chief Scientific Officer | May 6 '24 | Sell | $27.82 | 37,723 | $1,049,453.86 | 149,859 | SEC Form 4 |
| Michaelson Jennifer | CGEM | Chief Scientific Officer | May 6 '24 | Sell | $28.54 | 20,277 | $578,705.58 | 129,582 | SEC Form 4 |
| Michaelson Jennifer | CGEM | Chief Scientific Officer | May 6 '24 | Sell | $30.06 | 5,606 | $168,516.36 | 129,582 | SEC Form 4 |
| Savill Corrine | CGEM | Chief Business Officer | Feb 1 '24 | Sell | $16.18 | 40,000 | $647,200.00 | 165,990 | SEC Form 4 |
| Trigilio Jeffrey | CGEM | Chief Financial Officer | Dec 18 '23 | Sell | $8.22 | 398 | $3,271.56 | 85,839 | SEC Form 4 |
| Michaelson Jennifer | CGEM | Chief Scientific Officer | Dec 18 '23 | Sell | $8.22 | 238 | $1,956.36 | 88,727 | SEC Form 4 |
| Trigilio Jeffrey | CGEM | Chief Financial Officer | Dec 12 '23 | Sell | $7.81 | 1,926 | $15,042.06 | 86,237 | SEC Form 4 |
| Michaelson Jennifer | CGEM | Chief Scientific Officer | Dec 12 '23 | Sell | $7.81 | 1,068 | $8,341.08 | 88,965 | SEC Form 4 |
Latest Cullinan Oncology Inc. News
CGEM Breaking Stock News: Dive into CGEM Ticker-Specific Updates for Smart Investing
MT Newswires
4 days ago
HC Wainwright Adjusts Price Target on Cullinan Oncology to $28 From $29, Maintains Buy Rating
GlobeNewswire
5 days ago
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
GuruFocus.com
11 days ago
Insider Sale at Cullinan Therapeutics Inc (CGEM): Chief Scientific Officer Jennifer Michaelson ...
MT Newswires
19 days ago
Stifel Initiates Cullinan Oncology With Buy Rating, $40 Price Target
GlobeNewswire
21 days ago
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
Benzinga
a month ago
Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?
GlobeNewswire
a month ago
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
Benzinga
a month ago